Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15132385 | 0.90 | TSHR (0.47) | TSHRCYP2D6SMN1; SMN2VNN1 | |
| SCHEMBL21965097 | 0.90 | TSHR (0.42) | TSHRCYP2D6SMN1; SMN2HRH3VNN1 | |
| SCHEMBL18806138 | 0.88 | TSHR (0.41) | TSHRCYP2D6SMN1; SMN2 | |
| SCHEMBL19122632 | 0.88 | TSHR (0.49) | TSHRCYP2D6SMN1; SMN2VNN1 | |
| SCHEMBL24329447 | 0.88 | TSHR (0.39) | TSHRCYP2D6SMN1; SMN2 | |
| SCHEMBL19083180 | 0.84 | TSHR (0.41) | TSHRCYP2D6 | |
| SCHEMBL22359000 | 0.83 | TSHR (0.59) | TSHRSMN1; SMN2OPRM1OPRL1 | |
| SCHEMBL10296343 | 0.83 | — | — | |
| SCHEMBL24847484 | 0.82 | CYP2D6 (0.46) | TSHRCYP2D6SMN1; SMN2 | |
| SCHEMBL20070818 | 0.82 | TSHR (0.40) | TSHRCYP2D6HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | CORCEPT THERAPEUTICS INCORPORATED (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | CORCEPT THERAPEUTICS INCORPORATED | 2023-02-02 | — | — | US | disclosed |
| WO-2022133285-A1 | MOLECULES AND METHODS RELATED TO TREATMNET OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022011204-A1 | SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-01-13 | — | — | WO | disclosed |
| EP-3805218-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | Syros Pharmaceuticals, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| WO-2020160193-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | SYROS PHARMACEUTICALS, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2017-06-22 | — | — | US | disclosed |
| EP-3085695-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2016-10-26 | — | — | EP | disclosed |
| WO-2015093534-A1 | SUBSTITUTED TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | 日産化学工業株式会社 | 2015-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787780-B2 | Quaternary indazole glucocorticoid receptor antagonists | NR3C1, NR3C2, MC2R | TSHR 185/4885CYP2D6 303/4885SMN1; SMN2 4861/4885 |
| US-20230032612-A1 | QUATERNARY INDAZOLE GLUCOCORTICOID RECEPTOR ANTAGONISTS | NR3C1, NR3C2, MC2R | TSHR 185/4885CYP2D6 303/4885SMN1; SMN2 4861/4885 |
| US-10336760-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | TSHR 3486/4885CYP2D6 1821/4885SMN1; SMN2 3012/4885 |
| US-20170174692-A1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | CDK7, CDK3, CDK9 | TSHR 3486/4885CYP2D6 1821/4885SMN1; SMN2 3012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.